Hawthorne, New York, December 1, 2003 – Taro Pharmaceutical Industries Ltd. (NASDAQ: TARO) today announced the completion of a $50 million offering of long-term, non-convertible debt to institutional investors in Israel. Approximately $47 million of the debt issued in the offering was received in
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Nov. 12, 2003--Taro Pharmaceutical Industries Ltd. (Nasdaq/NMS: TARO) reported today that its U.S. affiliate has received tentative approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for fluconazole tablets
HAWTHORNE, N.Y., Sep 23, 2003 /PRNewswire via COMTEX/ -- Get ready for the biggest innovation in children's products since disposable diapers! Just in time for back-to-school runny noses and cold and flu season, Taro Pharmaceuticals introduces ElixSure(TM), a line of spill-resistant single-symptom
HAWTHORNE, N. Y.--(BUSINESS WIRE)--July 24, 2003-- 30th Consecutive Quarter of Record Sales; 20th Consecutive Quarter of Record Net Income Second Quarter 2003 Highlights: -- Sales Increase 51% to $74.8 Million -- Gross Profit Increases 62% to $50.0 Million -- Net Income Increases 45% to $14.8
HAWTHORNE, N.Y.--(BUSINESS WIRE)--July 10, 2003--Taro Pharmaceutical Industries Ltd. (Nasdaq/NMS: TARO) intends to report financial results for the second quarter of 2003 prior to the Nasdaq market opening on Thursday, July 24, 2003. The Company will conduct a conference call to discuss the results
HAWTHORNE, N.Y., Jun 23, 2003 (BUSINESS WIRE) -- Taro Pharmaceuticals U.S.A., Inc., the U.S. affiliate of Taro Pharmaceutical Industries Ltd. (Nasdaq:TARO), today announced plans for the August 2003 launch of a line of OTC cough and cold products based on the Company's patented NonSpil(TM) liquid
HAWTHORNE, N.Y., Jun 2, 2003 (BUSINESS WIRE) -- Taro Pharmaceutical Industries Ltd. (Nasdaq/NMS:TARO) today announced the completion of its previously announced offering of $60 million in long-term, non-convertible debt to certain banks and institutional investors in Israel.
HAWTHORNE, N.Y.--(BUSINESS WIRE)--May 22, 2003--Taro Pharmaceutical Industries Ltd. (Nasdaq/NMS:TARO) today announced that the Company intends to offer up to $60 million in long-term, non-convertible debt solely to Israeli banks and institutional investors in Israel.
HAWTHORNE, N.Y., Apr 16, 2003 (BUSINESS WIRE) -- Taro Pharmaceutical Industries Ltd. (Nasdaq/NMS: TARO): First Quarter Highlights -- Sales Increase 55% to $69.0 Million -- Net Income Increases 42% to $14.0 Million, or $0.47 per Diluted Share -- Etodolac Extended-Release Tablets ANDA Approved in the